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Critical appraisal of 3-monthly paliperidone depot 
injections in the treatment of schizophrenia
Bernardo Carpiniello
Federica Pinna
Department of Public Health, Clinical 
and Molecular Medicine – Psychiatry 
Research Unit and Psychiatric Clinic, 
University Hospital, Cagliari, italy
Aims: Three-monthly injections of paliperidone palmitate (PP-3M) represent a new and 
recently introduced long-acting antipsychotic therapeutic option. This review focuses on avail-
able data relating to the efficacy and safety of PP-3M and its position in the current therapeutic 
scenario.
Method: An analysis of PubMed, Scopus, and ISI Web of Knowledge databases was conducted, 
and all available papers on PP-3M, including poster presentations, were selected and considered 
for the purpose of the present review. Findings: to date, three full papers have been published, 
the first, a Phase 1 randomized, open label study investigating the pharmacokinetics, safety, 
and tolerability of the drug; the second, a Phase 3 double blind study vs placebo focusing on 
efficacy and tolerability; and the last relating to the practical use of PP-3M. The five posters 
identified describe data reported in the above-cited papers. Overall, the pharmacokinetic findings 
obtained in these studies highlight the feasibility of administering PP-3M on a 3-monthly basis, 
subsequent to the administration of four 1-monthly injections of PP at doses 3.5 times higher 
than the stabilized dose of 1-monthly injections of PP (ie, 175, 300, 450, and 525 mgs). The 
published studies highlight a significantly longer time to relapse compared to placebo, and sig-
nificantly better results compared to placebo for all secondary end-points (Positive and Negative 
Syndrome Scale, Clinical Global Impression-Severity Scale, Personal and Social Performance 
Scale scores), in addition to reasonably good safety and tolerability profiles.
Conclusion: PP-3M emerges as a potential candidate for use as a first-line long-acting agent 
in the maintenance treatment of patients with schizophrenia. Further studies should however be 
conducted to confirm this expectation. In view of its efficacy, tolerability, and safety, together 
with the longer timespan between injections, PP-3M currently represents one of the best avail-
able options, and may contribute towards addressing the issue of poor adherence, even in early 
psychosis.
Keywords: long-acting antipsychotics, 3-monthly paliperidone palmitate, efficacy, safety, 
pharmacokinetics, schizophrenia
Introduction
Schizophrenia is a severe and chronic disorder, causing significant impairment of 
functioning and quality of life, at tremendous human and social cost.1 The course of 
this disorder is characterized by periods of largely partial remission alternated with 
periods of relapse in approximately three quarters of all cases: the estimated relapse 
rate over 7–12 months following clinical stabilization in patients continuing antipsy-
chotic medications is 27%;2 approximately 80% of patients relapse within 5 years of 
the initial episode,3 with no more than 20% of subjects recovering completely after 
the first episode.4 Relapses frequently lead to hospitalization, poor treatment response, 
and further worsening of functioning.5 Following a relapse, one in six patients fails 
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to respond to treatment, and one in ten commits suicide;6 
symptomatic remission rates, evaluated according to defined 
strict criteria, are as low as 23% among chronic and/or 
patients with high recurrence rates.7 Episodes of recurrent 
illness seem to determine a progressive deterioration in the 
course of the illness.8 Indeed, time passed during relapses 
appears to be associated with a loss of gray and white matter,9 
while consecutive relapses are related to progressive loss in 
brain volume.10
Taken together, these data indicate how the prevention 
of relapse is a fundamental target in the treatment of schizo-
phrenia. Unfortunately, an effective continuity of pharma-
cological treatment is often difficult to achieve, mainly due 
to poor adherence,11,12 manifested in an average of 41% of 
patients affected by schizophrenia; in studies adopting more 
stringent criteria to evaluate treatment adherence, this per-
centage increases to 50% of patients.13
The problem of non-adherence would seem to be unre-
lated to the length of treatment, and generally occurs at a 
very early stage; it has been demonstrated that 30 days after 
discharge from hospital, less than 50% of patients pre-
scribed antipsychotic treatment were adherent.14 One of the 
major consequences of non-adherence is an increased risk 
of relapse, being approximately five times greater among 
patients who discontinue treatment.14 However, a multitude 
of other consequences should also be taken into consider-
ation, including increased risk of hospitalization, incomplete 
remission, impaired functioning, lower quality of life, sui-
cidality and self-harm behavior, aggressivity, substance mis-
use, and increased costs of treatment.11,12 Although a series 
of strategies has been developed to manage non-adherence, 
including accuracy in prescribing, or psychosocial interven-
tions including psychoeducation, behavioral or cognitive 
interventions, and motivational interviewing,11 the use of 
long-acting injections of antipsychotics (LAI) is probably 
the most widely used and simplest approach to combat 
non-adherence in common clinical practice, although use 
is generally limited to subjects who are partially or totally 
non-compliant to oral treatments.15,16 However, the benefits 
of LAI are not restricted solely to overcoming the problem 
of non-adherence, and due consideration should be given to 
the fact that they permit the physician to identify true lack of 
response (often difficult to evaluate in the case of partial or 
total non-adherence to oral treatments) and may foster more 
regular contact with caregivers. Moreover, they determine a 
better bioavailability, avoid first pass metabolism, establish 
more stable concentrations and a more predictable correlation 
between dosages and plasma levels, and reduce the risk of 
voluntary overdose.17
Although the ability of long-acting antipsychotics to 
enhance treatment adherence18,19 is widely acknowledged, 
there is still considerable ongoing debate with regard to the 
efficacy of depot vs oral antipsychotics. Indeed, one meta-
analysis20 demonstrated the superior efficacy of long-acting 
vs oral antipsychotics in reducing relapse, but a more recent 
meta-analysis study failed to demonstrate this difference, 
although a subgroup analysis yielded evidence of the greater 
effectiveness of long-acting first generation antipsychotics 
over oral drugs, but only when studies conducted up to 
1991 were considered.21 However, the results of randomized 
controlled trials (RCTs) taken into account in meta-analyses 
should be read in light of several limitations,22 which may 
lead to a bias in favor of oral antipsychotics. In particular, 
it should be kept in mind that patient samples selected for 
RCTs are not truly representative of patients seen in the 
“real world” of common clinical practice due to the pres-
ence of exclusion criteria (high severity, previous treatment 
resistance, relevant psychiatric comorbidity, suicidality 
etc). Moreover, the higher probability of partially adherent 
patients being excluded, or being more reluctant to take part 
in a clinical trial, should be taken into account.
Furthermore, even the most recent meta-analyses21 do not 
include the recently approved second generation long-acting 
antipsychotics administered by means of a once-monthly 
injection (paliperidone palmitate [PP] and aripiprazole). 
The so-called “mirror image studies” are considered meth-
odologically more appropriate in evaluating comparative 
effectiveness of antipsychotic formulations; it is worth men-
tioning that a recent meta-analysis of mirror image studies 
demonstrated the superiority of LAI over oral antipsychotics 
in preventing hospitalization.23 Nevertheless, evidence from 
mirror image studies should also be interpreted with caution 
in view of the major methodological limitation constituted by 
the lack of control groups. The findings of observational stud-
ies based on large administrative databases generally confirm 
the greater benefits afforded by LAI vs oral antipsychotics; 
in particular, a very recent study in the USA conducted on 
an extensive Medicaid multisite database of 3,768 patients 
who had received antipsychotics following discharge from 
hospital,19 demonstrated that LAI initiators displayed a lower 
odds of being non-adherent, and were characterized by con-
tinuous 60-day gaps between hospitalizations (only patients 
receiving second generation long-acting antipsychotics) 
compared to patients taking oral medication.
On the whole, available data support the notion that LA 
antipsychotics are at least more effective than oral medica-
tions in preventing more severe relapses requiring hospital-
ization. Several LA antipsychotic formulations are available 
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for the treatment of schizophrenia, both first generation 
(haloperidol, fluphenazine, flupentixol, pipotiazine zuclopen-
thixol), and second generation antipsychotics (risperidone, 
olanzapine, paliperidone, aripiprazole). This affords a greater 
choice of therapeutic options if long-acting treatment is 
viewed as the most appropriate in light of the patient’s needs 
and characteristics. Once-monthly PP (PP-1M) is a second 
generation LA agent, the efficacy, tolerability, and patient 
acceptability of which has been demonstrated in a relevant 
number of short- and long-term studies, both RCTs and open 
label studies.24 The present paper aims to review data pub-
lished to date relating to the formulation, pharmacokinetics 
(PK), pharmacodynamics, efficacy, safety, and acceptability 
of a new formulation of 3-monthly injections of PP (PP-3M), 
the newest LA antipsychotic featuring the longest duration 
of action currently available.
Methods
An electronic search of PubMed, ISI Web of Knowledge, and 
Scopus databases, without any time or language restriction, 
was performed up to November 31, 2015, using “Paliperidone 
Palmitate 3-Month”, “Paliperidone Palmitate 3-month for-
mulation” or “Paliperidone Palmitate 3-month injection” as 
keywords (Figure 1). References listed in selected papers 
were checked with the aim of identifying other potentially 
relevant papers. Poster presentations were specifically taken 
into account when data presented had not been published in 
full text articles. USA product inserts (PIs) were consulted 
for any useful information not published elsewhere.
Results
Three papers and five posters were thus identified. The first 
paper reported the results of a Phase 1, single dose, random-
ized, open label study conducted to investigate the PK, safety, 
and tolerability of PP-3M in patients with schizophrenia,25 
the second paper focused on the efficacy and safety of PP-3M 
emerging from a four phase RCT26 (Table 1), whilst the third 
related to practical issues implicated in the dosing and switch-
ing from PP-1M to PP-3M.27 Of the five posters retrieved, 
two28,29 reported data from the randomized clinical data more 
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Figure 1 Literature search flow diagram.
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extensively described in a paper by Berwaerts et al;26 the 
others30–32 reported data more extensively described in a paper 
by Ravenstijn et al.25 For the purpose of the present review, 
the main findings relating to the formulation, pharmacody-
namics and PK, safety, tolerability, and efficacy of PP-3M 
will be described, followed by the presentation of practical 
issues encountered while using this new formulation. The 
review will conclude with considerations of the position 
occupied by PPM-3M in the current therapeutic scenario.
PP-3M formulation
PP-3M is a new formulation of the palmitate salt ester of 
paliperidone (9-OH risperidone) based on a nanocrystal 
technology similar to that of PP-1M. Nanoparticles are usu-
ally defined as having a size between 1–1,000 nm. Tiny drug 
crystals are created and dispersed in an aqueous suspension 
(nanosuspensions). The only difference between PP-3M and 
PP-1M is the increased particle size of the former,25 which 
provides an extended sustained release of paliperidone, 
allowing a significantly higher dosing interval. In the same 
way as PP-1M, PP-3M is an admixture of PP enantiomers 
“wet milled” into nanoparticles characterized by a very low 
water solubility. These nanoparticles dissolve slowly after 
intramuscular (IM) injection before being hydrolyzed to 
paliperidone and adsorbed into the systemic circulation.
Pharmacodynamics
The putative mechanism of action of PP-3M in schizophrenia, 
similar to all other formulations of paliperidone, is elicited 
through a combined central dopamine antagonism on D
2
 and 
serotonin 5HT
2A
 receptor antagonism. Paliperidone displays 
α
1
, α
2
, and H
1
 antagonistic properties, but has no significant 
effect on cholinergic (muscarinic) and β
1
 or β
2
 receptors.33
PK
Nanoparticles of PP-3M dissolve slowly after IM injection 
before being hydrolyzed to paliperidone and adsorbed into 
the systemic circulation; release starts as early as day 1 and 
lasts for up to 18 months.33 In a study by Ravenstijn et al,25 
consisting of two open label periods after a 21-day screen-
ing phase, during the first week patients affected by schizo-
phrenia or schizoaffective disorder according to Diagnostic 
and Statistical Manual of Mental Disorders 4th Edition, 
Text Revision (DSMIV-TR) who had not previously taken 
Table 1 Summary of clinical studies
Study 
(authors, 
reference)
Aims Design Sample Main findings
Berwaerts 
et al,26 2016
To evaluate the efficacy 
and safety of the 3-monthly 
injections of paliperidone 
palmitate (PP-3M) vs placebo 
in delaying time to relapse of 
schizophrenia symptoms
Randomized, multicenter 
trial; four phases: 3-week 
screening phase; flexible 
dose 1-week open label 
transition phase; 12-week 
open label maintenance 
phase; open ended double 
blind phase
506 patients enrolled, 
DSMiv-TR diagnosis 
of schizophrenia; 305 
randomized to PP-3M 
(n=160) or placebo 
(n=145) in the double 
blind phase
Time to first relapse differed 
significantly, favoring PP-3M group 
over placebo
During the double blind phase 62% 
of patients receiving PP-3M and 
58% of those receiving placebo 
had at least one treatment-
emergent adverse event (TeAe); 
TEAEs observed significantly 
more frequently among patients 
treated with PP-3M compared to 
placebo included: headache (9% vs 
4%); weight increase (9% vs 3%); 
nasopharyngitis (6% vs 1%); and 
akathisia (4% vs 1%)
Ravenstijn 
et al,25 2015
evaluation of 
pharmacokinetics, safety 
and, tolerability of PP-3M 
in patients affected 
by schizophrenia or 
schizoaffective disorder
Multicenter, randomized, 
open label, parallel-group, 
Phase 1 study
328 patients enrolled, 
affected by DSMiv-TR 
diagnosis of schizophrenia 
or schizoaffective disorder
Peak paliperidone plasma 
concentration achieved between 
23 and 34 days; apparent half-life 
was 2–4 months; mean plasma 
AUC1 and Cmax appeared to 
be dose-proportional; relative 
bioavailability compared 
to paliperidone was 100%, 
independent of the dose and 
site of injection; headache and 
nasopharyngitis were the most 
common (.7%) TeAes
Abbreviations: DSMiv-TR, Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision; AUC1, ; Cmax, .
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risperidone or paliperidone (n=328, aged 18–65 years) 
received a 1 mg dose of paliperidone immediate release 
solution in a single IM (gluteal or deltoid) injection; dur-
ing the second period, which followed a washout period of 
7–21 days, patients received different doses (175, 300, 450, 
and 525 mgs) of PP-3M. Peak PP-3M was achieved between 
23 and 34 days, with an apparent half-life of 2–4 months, 
longer than that usually observed after PP-1M, a finding 
which substantiated the longer dosing interval of 3 months; 
mean AUC
1
 and C
max
 appeared to be dose-proportional with 
both gluteal and deltoid injection.
The site of injection was found to be an important factor in 
the PK of IM injections of PP. Indeed, following administra-
tion of PP-3M, the C
max
 of paliperidone was 27% higher in 
deltoid injection, with no difference in AUC
1
 between injec-
tion sites. These results, strikingly similar to those obtained 
with PP-1 M,34 are due to a difference in absorption rate likely 
caused by the adipose tissue overlying the gluteal muscle, 
with a consequent slower than usual uptake of PP follow-
ing deltoid injection. Ravenstijn et al25 suggested that these 
intra-injection site differences are not likely to be of clinical 
significance in view of the fact that PP-3M is designed to be 
administered only after four or more previous PP-1M injec-
tions, when plasma levels are nearing steady-state concentra-
tions. Minimal quantities of the prodrug were detected in 3% 
of patients after IM injection of PP-3M, a finding underlining 
how negligible amounts of the intramuscularly administered 
product reach the systemic circulation, and confirming that 
paliperidone is available only after cleavage. According to the 
authors of the same study,25 the PK parameters they observed 
differed only slightly compared to those cited in the USA PI33 
based on findings obtained from the pooled population of 
Phase 1 and 3 studies. Pharmacokinetic data collected during 
an efficacy and safety randomized controlled study published 
recently26 are reported as supplementary material; median 
plasma concentrations of paliperidone during the double blind 
(DB) phase after PP-3M injections overlapped with plasma 
concentrations observed in the transition phase (TP) after 
corresponding PP-1M injections for all dose groups (50 mg 
eq PP-1M vs 175 mg eq PP-3M; 75 mg eq PP-1M vs 263 mg 
eq PP-3M; 100 mg eq PP-1M vs 350 mg eq group).
According to the PI,33 following a single IM dose of 
PP-3M, plasma concentrations of paliperidone gradually 
increase, reaching maximum plasma concentrations at a 
median T
max
 of 30–33 days; injections in the deltoid muscle, 
on average, were determined to have an 11%–12% higher 
C
max
. The release profile and dosing regimen of PP-3M 
have resulted in sustained concentrations over 3 months. 
The total and peak exposure of paliperidone after PP-3M 
administration was dose-proportional over a 273–819 mg 
dose range. The mean steady-state trough:peak ratio for a 
dose of PP-3M was 1.6 after gluteal, and 1.7 after deltoid 
injection. The apparent volume of distribution is 1,960 L and 
plasma protein binding is 74%. The reported median half-
life of paliperidone following a dose range of 272–819 mg 
PP-3M IM is comprised between 84–95 days when injected 
in the deltoid, and 118–139 days for gluteal injections. At a 
dose of 819 mg of PP-3M, plasma concentrations detected 
18 months after the last dose were 3% and 7%, respectively, 
the average steady-state levels following deltoid and gluteal 
injections.
With regard to metabolism and elimination, PI33 reports 
information from studies relating to oral PP: approximately 
59% of a single dose of the drug is excreted unchanged in 
the urine; approximately 80% of the radioactivity related to a 
single oral dose of 14C paliperidone was recovered in the urine 
and 11% in the feces, indicating a lack of extensive hepatic 
metabolization. Results obtained in in vitro studies have 
suggested that CYP2D6 and CYP3A4 may be implicated 
in the metabolism of PP, although no evidence of their role 
derived from in vivo studies has been reported. Due to the 
lack of specific drug interaction studies relating to PP-3M, 
data reported in PIs33 are derived from studies investigating 
oral PP, showing a substantial lack of evidence from in vivo 
studies in support of the hypothesis that inhibitors or induc-
ers of CYP2D6 and CYP3A4 may significantly influence 
PP plasma levels; moreover, no significant inductive or 
inhibitory properties of PP on the cytochrome system have 
been demonstrated. Analogously, data obtained in special 
populations or conditions are largely based on studies of oral 
PP:33 no significant modifications of plasma concentrations 
of the drug have been reported based on age, slight/moderate 
hepatic impairment or smoking, although slower absorption 
rates were found among females; following PP-3M injections 
no differences in plasma levels were reported at apparent 
steady-state between sexes. Similarly, although a lower 
C
max
 was found in overweight and obese subjects, at appar-
ent steady-state with PP-3M, no weight-related differences 
in plasma levels were revealed. Finally, a comparison of 
PP-3M with other PP formulations33 found that PP-3M, when 
administered at doses 3.5-fold higher than the corresponding 
dose of PP-1M, resulted in paliperidone exposures similar 
to those of a corresponding PP-1M dose, or a corresponding 
daily dose of PP extended-release tablets.
Efficacy
Efficacy of PP-3M vs placebo was evaluated in a multi-
center RCT conducted in eight countries on 506 patients 
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(aged 18–70 years) affected by schizophrenia according to 
DSMIV-TR. Ninety-one percent (n=462) of patients enrolled 
were receiving psychotropic medication before enrollment: 
63% (n=318) oral atypical antipsychotics, 23% (n=118) 
typical antipsychotics, and 18% (n=89) depot antipsychot-
ics (7%, N=36, PP-1M). The study consisted of four phases: 
a 3-week screening phase, a flexible-dose open label TP, a 
12-week open label maintenance phase (MP), and a one-
ended DB phase.
During the TP patients were treated with PP-1M doses 
(50, 75, 100 or 150 mg eq), with the exception of subjects 
switching from other LAI, or those previously treated with 
PP-1M prior to recruitment to the study. At the start of MP 
patients received a single dose of PP-3M (deltoid or gluteal) 
3.5-fold higher than the stabilized dose of PP-1M during MP, 
ie, 175, 263, 350, and 525 mg eq. In the DB phase, 305 of the 
506 patients enrolled were randomized to PP-3M and 145 to 
placebo. Patients entering the DB phase were aged ~38 years, 
predominantly male (75%) and white (64%), previously 
hospitalized once or more during their lifetime (64%), with 
a mean body mass index of ~26, who had not been on depot 
prior to the start of the study (83%).
Patients’ clinical severity at the start of DB phase was 
mild (mean total Positive and Negative Syndrome Scale score 
54.5, mean Clinical Global Impression-Severity Scale total 
score 2.7; mean PSS score 68.7). The primary efficacy vari-
able was time from randomization to first relapse. The pro-
tocol envisaged an interim efficacy analysis after 42 episodes 
of relapse and a final analysis after 70 episodes of relapse, 
if the study had not been terminated previously at interim 
efficacy analysis. Interim analysis of 284 patients (PP-3M 
n=148, placebo n=135) revealed a significant difference 
between the two groups, with a median time to relapse of 
274 days for the placebo group, which was not estimable 
for the PP-3M group (hazard ratio =3.45, 95% confidence 
interval 1-73-6.88, P,0.001). Twenty-three percent of 
subjects receiving placebo (n=31), and 7% (n=11) of those 
receiving PP-3M were relapsing. Based on these findings, 
an independent committee recommended early termination 
of the study for efficacy.
At the time of final analysis of the entire sample 
(n=305 patients), the superiority of PP-3M vs placebo in 
delaying time to relapse (hazard ratio =3.81, 95% confidence 
interval 2.08–6.99, P,0.001) was confirmed, with a median 
time to relapse, which was not estimable for PP-3M patients, 
and of 395 days for the placebo group. According to final 
analysis, 29% of the placebo group (n=42) and 9% of the 
PP-3M group (n=14) were relapsing. A higher efficacy of 
PP-3M over placebo was demonstrated irrespective of age, 
sex, race, body mass index or study site. Out of all patients 
randomized in the DB phase, 50% of PP-3M and 57% of 
placebo patients were remitted at DB baseline. Ninety-two 
percent of subjects receiving PP-3M were still in remission 
at week 36 compared to 58.3% of those receiving placebo. 
A decreased number of well-functioning patients (Personal 
and Social Performance Scale [PSP] total score .70) was 
detected in the placebo group (from 42% at DB baseline to 
32% at end-point), while PP-3M patients remained fairly 
stable (46% both at baseline and end-point). A number of 
secondary efficacy analyses supported the higher efficacy of 
PP-3M over placebo. Indeed, significant differences in mean 
variation from DB baseline to end-point were observed in 
scores obtained in several rating scales by patients receiving 
PP-3M compared to the placebo group (Table 2).
Table 2 Change from baseline mean scores of clinical and functioning scales in patients treated with PP-3M vs placebo*
Scales (mean, SD) Placebo (n=145) PP-3M (n=160) P-value
PANSS total score 6.7 (14.40) -0.5 (8.36) ,0.001
PANSS positive subscale 2.7 (4.92) -0.1 (2.84) ,0.001
PANSS negative subscale 0.8 (3.76) -0.1 (2.96) 0.013
PANSS general psychopathology subscale 3.2 (7.88) -0.3 (4.77) ,0.001
PANNS Marder standardized factor scores
Positive symptoms
Negative symptoms
Disorganized thought
Hostility/excitement
Anxiety/depression
2.5 (5.25)
0.4 (4.01)
0.7 (3.38)
1.7 (3.18)
1.4 (3.28)
-0.1 (2.74)
-0.3 (3.21)
-0.2 (2.53)
-0.0 (1.89)
0.1 (2.34)
,0.001
0.080
0.005
,0.001
,0.001
CGi-S score 0.4 (0.87) 0.1 (0.60) ,0.001
PSP total score -4.2 (9.70) -0.5 (6.63) ,0.001
Note: *See reference 26.
Abbreviations: PP-3M, 3-monthly injections of paliperidone palmitate; PANSS, Positive and Negative Syndrome Scale; CGi-S, Clinical Global impression-Severity Scale; PSP, 
Personal and Social Performance Scale; SD, standard deviation.
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Safety
In the study by Ravenstijn et al,25 during period 2, when 
a single dose of PP-3M was injected, 73.7% of patients 
experienced at least one treatment-emergent adverse event 
(TEAE), the majority of which were rated as mild or moder-
ate; taking into account the summary of data from all study 
panels, the most common included nasopharyngitis (11%), 
headache (9%), psychotic disorder or schizophrenia (6.2%), 
weight increase (5.2%), and back pain (5.2%). In the study 
by Bewaerts et al,26 65% of patients in the open label phase 
(n=330 over 506) and 60% (183 over 305 patients) in DB 
phase (62% of those on PP-3M, 58% of the placebo group) 
displayed at least one TEAE.
When considering only the most frequently manifested 
events, during the MP patients receiving PP-3M reported 
anxiety (6%), and insomnia (5%); very few patients discon-
tinued treatment, three (1%) due to “psychiatric disorders” 
and one (0.3%) due to “schizophrenia”. During the DB 
phase, compared to the placebo group, the most frequently 
manifested TEAEs in PP-3M treated patients were a higher 
than 7% weight increase (10% vs 1%), headache (9% vs 
4%, respectively), EPS (8% vs 3%, respectively), including 
akathisia (4% vs 1%, respectively), and nasopharyngitis (6% 
vs 1%, respectively). On the contrary, the most frequent 
TEAEs manifested by placebo-treated patients compared to 
those taking PP-3M were anxiety (11% vs 8%, respectively), 
insomnia (12% vs 7%, respectively), weight loss (8% vs 
1%), and glucose-related TEAEs (6% vs 3%). A summary 
overview of TEAEs registered in patients receiving PP-3M 
in Phase 1 and 3 studies is reported in Table 3. With regard to 
electrocardiography findings, abnormally elevated heart rate 
was detected in 7% vs 3% of patients, respectively. Patients 
with a change in QTc interval .30–60 msec from DB 
baseline records ranged from 3.2% to 6.9% among patients 
receiving PP-3M and from 2.8% to 5.5% among placebo-
treated subjects, according to the different formula utilized 
Table 3 Percentage of patients with treatment-emergent adverse events (TeAes) during Phase 1 and 3 studies of PP-3M
TEAEs Phase 1 study* Phase 3 study:** 
maintenance phase
Phase 3 study:** double 
blind phase
Placebo PP-3M
Nasopharyngitis 11.0% 0.0% 1.0% 6.0%
Headache 9.0% 3.0% 4.0% 9.0%
weight increase 5.2% 4.0% 3.0% 9.0%
weight loss 3.2% 0.0% 8.0% 1.0%
Decreased appetite 0.0% 0.0% 2.0% 1.0%
Back pain 5.2% 0.0%
ePS 0.0% 3.0% 3.0% 8.0%
Akathisia 0.0% 1.0% 1.0% 4.0%
Anxiety 4.5% 6.0% 11.0% 8.0%
Psychosis/schizophrenia 6.2% 4.0% 10.0% 1.0%
insomnia 3.5% 5.0% 12.0% 7.0%
irritability 0.0% 0.0% 2.0% 2.0%
Agitation 0.7% 0.0% 2.0% 1.0%
Suicidal ideation 1.0% 0.0% 2.0% 0.0%
Depression 3.6% 0.0% 0.0% 0.0%
Diarrhea 3.6% 0.0% 0.0% 0.0%
Tachycardia 3.6% 0.0% 0.0% 0.0%
Abdominal pain 3.2% 0.0% 0.0% 0.0%
Other aches 4.2% 0.0% 0.0% 0.0%
Upper respiratory tract infections 2.9% 0.0% 2.0% 4.0%
Urinary tract infections 0.0% 0.0% 1.0% 3.0%
Cough 0.0% 0.0% 2.0% 3.0%
Influenza 0.0% 0.0% 2.0% 2.0%
Prolactin related TeAes 0.0% 0.0% 0.0% 1.0%
Amenorrhea 0.0% 0.0% 0.0% 2.0%
vomiting 0.6% 0.0% 0.0% 0.0%
Pain at injection site 8.1% 0.0% 0.0% 4.0%
Diabetes mellitus 0.6% 0.6% 6.0% 0.0%
Total 73.7% 24.8% 62.0% 58.0%
Notes: *See reference 25; **see reference 26.
Abbreviations: PP-3M, 3-monthly injections of paliperidone palmitate; ePS, .
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for calculation of QTc. An increase of QTc .60 msec was 
observed in only one patient (,1%) treated with PP-3M dur-
ing the OL phase, and no patients manifested a QTc increase 
over 480 msec at any point in the study.
With regard to weight, the mean increase from OL base-
line (which included the OL TP, characterized by several 
doses of PPM-1M followed by one single dose of PP-3M) 
and to DB end-point was significantly higher among patients 
treated with PP-3M compared to placebo (2.38 vs 0.55 kg, 
respectively). A few TEAEs were registered in PM-3M 
patients alone: injection site TEAE (4%, of which 2% was 
pain), PRL increase (1%), and amenorrhea (2%). To summa-
rize, serious TEAEs were registered with an approximately 
4-fold higher frequency in the placebo group compared to 
PP-3M group (10% vs 3%, respectively), and were gener-
ally represented by worsening of psychiatric symptoms, 
with only one hepatic TEAE (increased transaminase level) 
leading to treatment discontinuation in the DB phase in the 
placebo group; one patient treated with PP-1M died during 
the open label phase due to complications from megacolon, 
a death which was not deemed to be related to the study drug. 
Overall, discontinuation due to adverse events occurred in 
5.1% of patients during the long-term, open label, MP, with 
no discontinuation during the DB phase.
Practical issues for dosing and 
switching
Based on published studies, Gopal et al27 have provided guid-
ance for the practical use of PP-3M. In particular, switching 
to PP-3M is only recommended in patients who have previ-
ously been treated with PP-1M for at least 4 months; the first 
injection should be given at the time of the first scheduled 
administration of PP-1M, with a dosing window of ±1 week. 
A dose of PP-3M corresponding to 3.5 times the last dose 
of PP-1M, ie, 175 mg eq of PP-3M substitute; 70 mg eq of 
PP-1M, should be administered. Following the first injection, 
PP-3M should be given once every 3 months with a dosing 
window of ±2 weeks, resulting in the need for approximately 
four injections per year. PP-3M doses may be administered 
in either deltoid or gluteal muscle using a 1.5 22 G needle, 
although if deltoid injection is given to a person ,90 kg, a 
1.0 inch 22 G needle would be preferable. In the case of mild 
renal impairment, evidenced by creatinine clearance ranging 
between 50 and 80 mL/min, a 25% dose reduction of PP-1M 
should be applied, with a subsequent switch to a 3.5 dose 
multiple of PP-3M, which should not exceed the maximum 
dose of 350 mg eq. In elderly subjects with reduced renal 
function (limited to mild impairment) a similar adjustment 
of dosing is recommended. The use of PP-3M in patients of 
any age with moderate/severe renal impairment should be 
avoided. However, no dose adjustment of PP-3M is required 
in patients of any age with mild or moderate hepatic impair-
ment, or in elderly patients with normal renal function.
PP-3M: summary of evidence, 
position in the therapeutic scenario, 
and future developments
Introduction of LAI constituted one of the first examples of 
the efforts made to overcome the problems of non-adherence 
in an area of psychopathology, such as psychotic disorders, in 
which very long-term treatments are the general rule. It is an 
acknowledged fact that adherence can be improved using the 
currently marketed LAI, although non-compliance continues 
to persist even when prescribing these formulations.11 Thus, 
continuous research by the pharmaceutical industry aimed at 
introducing new formulations featuring an extended duration 
of action is of fundamental importance. Indeed, the main 
reason underlying the development of PP-3M was to obtain 
a drug formulation capable of extending dosing intervals 
in order to reduce non-adherence compared to the other 
currently available LAI.26
The real advantage of this new formulation of PP-3M is 
the possibility of simplifying the therapeutic regimen as much 
as possible, with the aim of increasing treatment acceptance 
by frequently reluctant or otherwise uncooperative patients. 
Another advantage may be the reduced dosing frequency 
for patients with limited access to health care. Overall data 
from published studies clearly indicate the efficacy and 
safety of PP-3M, substantially similar to that obtained with 
PP-1M in long-term treatment, and in preventing relapse in 
patients affected by schizophrenia.34 Indeed, PP-3M not only 
significantly delays the time to recurrence, but has proved 
capable of further reducing the severity of psychopathology 
in patients stabilized with PP-3M; moreover, these evident 
clinical improvements are paralleled by the progressive 
amelioration of personal and social functioning, as shown 
not only by the improvement of PSP scores, but also by the 
large number of patients (46%) who, on completion of the 
DB phase of treatment, maintained the good functioning (ie, 
a PSP total score .70) displayed at baseline.26
As regards safety and tolerability,25,26 the most common 
adverse events, including EPS and weight gain, are generally 
manifested in no more than 10% of cases, being generally of 
low or moderate severity. Metabolic and cardiologic safety 
is a finding of noteworthy clinical importance, particularly in 
view of the almost insignificant rate of severe adverse events. 
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Unfortunately, studies published to date have failed to 
address the problem of patients’ subjective perceptions of 
the drug, although the very low rate of withdrawal of consent 
by subjects receiving PP-3M (4%) both in the maintenance 
and DB phase may be considered a proxy of more specific 
measures of personal perception of the drug, indicating a 
fairly good acceptance of PP-3PM. However, in light of the 
knowledge that PP-3M is a “young” formulation supported 
by a limited number of studies, these promising data will 
need to be confirmed in future research studies. In particular, 
additional long-term studies should be undertaken to confirm 
the available data, as occurred previously for PP-1M.34–41 In 
particular, we expect to see further information from “natu-
ralistic” studies, which were pivotal in providing significant 
confirmation of the effectiveness of PP-1M in “real world” 
schizophrenic populations, such as those with physical and 
psychiatric comorbidity, including drug abuse.42–44
As mentioned previously, specific concerns are focused 
on the patient’s subjective perception and acceptance of the 
new formulation; no studies have been conducted to date to 
verify the latter, although positive results, similar to those 
emerging from PP-1M studies45 may be expected. The use 
of a very long-term active formulation such as PP-3M may 
give rise to further concerns among mental health profes-
sionals who are critical of the use of these formulations.46 In 
particular, several aspects should be taken into consideration: 
the risks implicated due to the persistence of side-effects, 
the risk of a reduced involvement of mental health staff 
in patient care, the presumed negative appraisal of these 
formulations by patients, and the coercive nature of this 
type of care. With regard to the first point, persistence of 
side effects in subjects in whom the drug is suspended due 
to safety concerns is fortunately a rare event, as attested by 
the available safety data relating to severe adverse events in 
patients treated with LAI, including PP-3M. Regarding the 
second point, to what extent the use of LAI actually results 
in a diminishing of clinical care of the patient is a matter of 
debate, particularly in view of a lack of reliable data. It would 
however seem to be an inherent problem in the professional 
and educational setting, work ethics, and staff resources of 
community teams rather than an intrinsic problem linked to 
LAI therapy. As to the presumed negative appraisal of the 
drug, data from literature seem to disprove this assumption, as 
LAI, including PP-1M, are generally well accepted.46 Lastly, 
with regard to the hypothesized coercive nature of LAI, it 
should be underlined how, as a general ethical principle, all 
treatment should be given on a voluntary basis, with the sole 
exception of involuntary treatments provided and regulated 
by law throughout the majority of countries; the creation 
of a valid therapeutic alliance, the acquisition of informed 
consent, and of adequate adherence to treatment is one of the 
fundamental duties of psychiatrists, and forms the basis of 
an effective treatment. In our opinion, it is not the drug that 
is coercive per se, but rather the means adopted in fulfilling 
a duty of care.
To conclude, with regard to the position occupied by 
PP-3M in the range of therapeutic options for the treatment of 
psychoses, LAI have been viewed in authoritative guidelines 
and by leading experts in the field as a fundamental option 
in the long-term treatment of schizophrenia.47,48 Indeed, this 
type of formulation will likely occupy an extremely relevant 
position, particularly in view of its singular pharmacokinetic 
properties and the possibility of simplifying and rendering the 
process of long-term care more acceptable. However, the risk 
of LAI being confined to use in the maintenance of only very 
chronic cases, often being seen as a “last resort” treatment 
for a large number of psychiatrists, should be discussed.54 
Several keynote experts49,50 maintain that it may be advis-
able to consider the issue from another perspective, namely 
the use of LAI in the early treatment of psychoses, although 
data from literature reveal that psychiatrists are frequently 
reluctant to prescribe LAI in general, and particularly for the 
treatment of first episodes and in young people.51
The suggestion to use LAI in the treatment of early 
psychosis is based upon preliminary evidence attesting the 
superiority of LAI-SGAs over oral SGAs in controlling 
negative symptoms and psychosocial functioning, as well 
as the potential superiority of LAI in the early detection 
of high rates of non-adherence in first-episode patients, 
and consequent reduction of the number of relapses and 
hospitalizations.51,52 Moreover, the opinion widely held by 
psychiatrists that young people are extremely reluctant to 
accept depot injections seems to be confuted by the optimal 
acceptance of therapy shown in a recent study.53 Although 
the paucity of studies available and the methodological 
limitations of studies relating to LAI in early psychoses do 
not allow any firm conclusions to be reached, the early use 
of LAI subsequent to initial episodes seems to be worthy of 
consideration, at least in early cases displaying a clear prob-
lem of non-adherence. Thus, in view of the lower number of 
injections required, in these cases it is likely reasonable to 
anticipate an improved acceptance of PP-3M compared to 
other LAI. Taken together, this potential for improved treat-
ment acceptance and the presence of a reasonably good safety 
profile contribute towards proposing PP-3M as a first-line 
therapeutic option.
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